HeartSciences Named Among ‘50 Smartest Companies of the Year 2018’ by The Silicon Review Magazine

HeartSciences Named Among ‘50 Smartest Companies of the Year 2018’ by The Silicon Review Magazine

Southlake, Texas – Silicon Review, a leading Business and Technology magazine has named HeartSciences, as one of the 50 Smartest Companies of the Year 2018.

The Silicon Review 50 Smartest Companies of the Year 2018 program identifies companies that mastered the discipline of smartness and stood high among the crowd,” said Sreshtha Banerjee, Editor-in-Chief of The Silicon Review Magazine.

We are honored to be recognized by The Silicon Review Magazine as the one of the 50 Smartest Companies of 2018,” said Mark Hilz, CEO at HeartSciences. “HeartSciences use of patented signal processing methods combined with artificial intelligence is designed to bridge today’s “diagnostic gap” in cardiac care by providing low-cost effective solutions that help to identify cardiac dysfunction in the diastolic phase.”

See Full Article

HeartSciences Showcases MyoVista® Wavelet ECG at 2018 European Society of Cardiology Congress (ESC)- Hall A, Booth G320

HeartSciences Showcases MyoVista® Wavelet ECG at 2018 European Society of Cardiology Congress (ESC)

Hall A, Booth G320

 

SOUTHLAKE, Texas, August 20, 2018 –(BUSINESSWIRE)—HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing and artificial intelligence is proud to announce its participation as an exhibitor at the upcoming 2018 European Society of Cardiology Congress (ESC). The Congress will take place at Messe Munich International in Munich, Germany and will run from August 25 to August 29, 2018. HeartSciences will highlight it’s MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device as well as recent clinical study results published in the Journal of the American College of Cardiology (JACC)

The JACC article titled “Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG” presented the results from the investigator-initiated clinical study that focused on evaluating the feasibility of MyoVista® Wavelet ECG as a diagnostic tool for predicting myocardial relaxation abnormalities. Results from the study demonstrate MyoVista’s patented technology based on CWT signal processing can detect myocardial relaxation abnormalities associated with LVDD.

About HeartSciences

HeartSciences is advancing the field of electrocardiography through the application of wavelet signal processing and artificial intelligence to develop next generation ECG technology. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista wavECG Cardiac Testing Device is a 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease.

In addition to the proprietary informatics, the MyoVista wavECG Device also features the capabilities of a full featured 12-lead resting ECG including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training as well as easy and intuitive use. The MyoVista wavECG Device is not currently approved for sale or distribution in the United States and is not currently FDA cleared.

HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.

For more information visit www.heartsciences.com.

Contacts

HeartSciences
Gene Gephart, +1-737-346-1089
gene.gephart@heartsciences.com

 

Investor Contact

Zimmons International Communications

Jennifer K. Zimmons, +1-917-214-3514

jzimmons@zimmonsic.com

 

 

 

HeartSciences Showcases MyoVista® Wavelet ECG at the 2018 International Congress on Electrocardiology (ICE)

SOUTHLAKE, Texas, June 25, 2018 –(BUSINESSWIRE)—HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 International Congress on Electrocardiology (ICE), which will be held in Makuhari Messe, Chiba City, Japan, June 28-30, 2018. ICE2018 will be the joint meeting of the 45th Congress of the International Society of Electrocardiology (ISE) and the 18th Congress of the International Society for Holter and Noninvasive Electrocardiology (ISHNE). This Congress will focus on Electrocardiography, from noninvasive diagnosis to prognosis covering basic electrophysiology, novel signal processing methods of Holter ECG, prognostic ECG techniques for preventing sudden cardiac death, applications of antiarrhythmic agents and direct oral anticoagulants, a critical role of catheter ablation for tachyarrhythmias and appropriate use of implantable devices.

About HeartSciences

HeartSciences is leading innovation in the field of electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista® Wavelet ECG (wavECG™) is a first-to-market 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease.

In addition to proprietary informatics, the MyoVista wavECG Device has full 12-lead resting ECG capabilities including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training with no change in ECG clinical workflow. The MyoVista wavECG Device is not currently FDA approved for commercial sale or distribution in the United States.

HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.

For more information visit www.heartsciences.com.

Contacts

HeartSciences
Gene Gephart, +1-737-346-1089
gene.gephart@heartsciences.com

MedTech Strategist Names HeartSciences as Start-Up to Watch

HEARTSCIENCES:
Artificial Intelligence Improves Frontline Risk Stratification for Heart Diseases

The current screening paradigm for heart disease is missing people at early stages, when diseases are most treatable. HeartSciences has taken a ubiquitous screening tool, the 12-lead ECG, and has, through the application of signal processing and artificial intelligence, turned it into a powerful tool that can detect diastolic dysfunction, an early indicator of most cardiac diseases.

HeartSciences: AI Improves Frontline Risk Sratification for Heart Diseases

 

HeartSciences Announces Professor Peter Macfarlane Joins Clinical Advisory Board

Professor Peter W. Macfarlane, DSc eFESC FRSE, is an expert in the field of electrocardiology and has over 40 years’ experience in the development of computer-based systems for the interpretation of ECGs. He has authored over 300 publications and peer-reviewed papers, as well as numerous books on the subject. Professor Macfarlane is recognized as a pioneer in the use of computers in hospital-based ECG interpretation. The work of his team has been adopted commercially, and the University of Glasgow ECG interpretation analysis developed in his laboratory is currently used worldwide. The Glasgow analysis is incorporated in the MyoVista® wavECG™ Device where it complements HeartSciences by providing computerized analysis of the conventional ECG waveform. At present, he is Emeritus Professor and Honorary Senior Research Fellow of the University of Glasgow. In 2014, Professor Macfarlane was awarded a CBE for services to British healthcare.

 

Peter is the current President of the International Society of Computerized Electrocardiology (ISCE). He also serves as Treasurer of the International Society of Electrocardiology (ISE), having been President in the past. His major interest throughout his career has been the application of computer techniques to ECG interpretation.

 

“HeartSciences’ use of computerized techniques, such as signal processing and artificial intelligence, is truly innovative.  I look forward to contributing to HeartScience’s success,” said Macfarlane.

 

“HeartSciences is honored to have Peter join our Clinical Advisory Board. His wealth of experience and expertise in the application of computer techniques in electrocardiology aligns well with the company’s technology and vision for the future,” said Mark Hilz, chief executive officer of HeartSciences. “We look forward to working with Peter to achieve our shared goals of improving ECG capabilities for the detection of heart disease.”

 

About HeartSciences

HeartSciences is leading innovation in the field of electrocardiology through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista® Wavelet ECG (wavECG™) Device is a first-to-market 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy-related information rather than conventional voltage-based information. HeartSciences’ mission is to enable accurate, affordable screening for the early detection of heart disease.

In addition to proprietary informatics, the MyoVista wavECG Device has full 12-lead resting ECG capabilities including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device, requiring minimal user training with no change in ECG clinical workflow. The MyoVista wavECG Device is not currently available for commercial sale or distribution in the United States.

HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.

For more information visit www.heartsciences.com.

HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC)

HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC)

Study demonstrates promising new capabilities for MyoVista® ECG device in detecting Abnormal Cardiac Function

HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC)

HeartSciences Announces Poster Presentation at the 2018 American College of Cardiology Scientific Sessions

Poster Title: Prediction of Cardiac Mechanical Relaxation Abnormalities from Surface ECG Wavelets

Date: Sunday, March 11, 2018 at 3:45 p.m.

Location: Orange County Convention Center | 9800 International Drive | Orlando, Florida 32819 USA | Hall A/B

Poster: 1238-107

HeartSciences will participate in the Future Hub at ACC 2018. Future Hub is a multi-vendor educational venue to inform, educate and inspire ACC 2018 attendees by exposing them to the latest innovations in Digital Health, Medical Devices, and Ed Tech (Educational Technology). HeartSciences will be located at space FH7 of the Future Hub to present the MyoVista® spECG™ technology.

About HeartSciences

HeartSciences is advancing the field of electrocardiography through the latest research in heart disease in combination with the application of the latest technology. HeartSciences applies wavelet signal processing and artificial intelligence to develop breakthrough ECG technology. Wavelet signal processing is used in many different industries as a valuable tool that provides insights and new valuable data related to spectral analysis of a signal.

HeartSciences, a Fierce Innovation Award Finalist, will present at Biotech Showcase Events in San Francisco on January 9 and 10, 2018

HeartSciences Logo

 

SOUTHLAKE, TEXAS – January 3, 2018 – HeartSciences, a medical device company recently selected as a finalist for the Fierce Innovation Awards in the Digital Health Solution category, will be presenting in San Francisco at the BioTech Showcase.  HeartSciences has two scheduled presentations: (1) Tuesday, January 9 at the BioTech Showcase at 2:45pm at the Hilton Hotel, Union Square and (2) Wednesday, January 10 at the Digital Medicine and Technology Showcase at 10.00am, at the Parc 55 Hotel.

 

HeartSciences is advancing the field of electrocardiology in combining the latest research and understanding of heart disease with the patented use of wavelet mathematics and artificial intelligence to develop medical devices for the early detection of heart disease.  Its MyoVista hsECG (high sensitivity ECG), is designed to significantly improve the sensitivity of a diagnostic electrocardiology device in detecting ischemic and structural heart disease at an early stage.  Through the patented use of Continuous Wavelet Transform digital signal processing it measures the heart’s energy during its cardiac cycle. Recent clinical trials demonstrate MyoVista’s ability to detect cardiac dysfunction in the diastolic phase, which is known as Diastolic Dysfunction. The MyoVista hsECG, includes all the conventional information of a full featured 12-lead resting ECG plus new energy related informatics assisting in the early detection of heart disease.

 

HeartSciences was selected as a Fierce Innovation Award Finalist in December 2017 for its innovative, MyoVista® hsECG™ (high sensitivity ECG) device. Finalists were selected from a highly competitive list of innovators by a distinguished panel of judges. All applications were evaluated based on the following criteria: Competitive Advantage, Financial Impact/Value, Market Need, and Overall Innovation. Applicants with the top 3 scores in each category were selected as finalists.  Life Sciences Edition 2017, is an awards program from the well-known e-publisher of FierceBiotech and FiercePharma.

 

About HeartSciences

HeartSciences is advancing the field of electrocardiology in combining the latest research and understanding of heart disease with the patented use of wavelet mathematics and artificial intelligence to develop medical devices for the early detection of heart disease.  HeartSciences is bridging today’s “diagnostic gap” in cardiac care by developing new low-cost effective solutions that assist in identifying at-risk patients.

 

HeartSciences’ MyoVista® hsECG™ Cardiac Testing Device is a new 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. It’s patented signal processing method measures myocardial energy during the cardiac cycle. Proprietary informatics focus on abnormalities related to cardiac energy levels in addition to providing traditional ECG information.

 

In addition to the proprietary informatics, MyoVista hsECG also features the capabilities of a full featured 12-lead resting ECG including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms.

 

HeartSciences (formerly known as Heart Test Laboratories) is a privately-held U.S. corporation based in Southlake, Texas.

 

For more information visit www.heartsciences.com.

 

Corporate contact

Gene Gephart

+1 737 346 1089

gene.gephart@heartsciences.com